Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SNY 
Sanofi ADR (SNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: SNY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -3.81% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 135.77B USD | Price to earnings Ratio 23.2 | 1Y Target Price 63.72 |
Price to earnings Ratio 23.2 | 1Y Target Price 63.72 | ||
Volume (30-day avg) 2696586 | Beta 0.46 | 52 Weeks Range 45.22 - 60.12 | Updated Date 04/1/2025 |
52 Weeks Range 45.22 - 60.12 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 3.67% | Basic EPS (TTM) 2.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 12.56% | Operating Margin (TTM) 13.99% |
Management Effectiveness
Return on Assets (TTM) 4.28% | Return on Equity (TTM) 7.3% |
Valuation
Trailing PE 23.2 | Forward PE 12.25 | Enterprise Value 148601118299 | Price to Sales(TTM) 3.07 |
Enterprise Value 148601118299 | Price to Sales(TTM) 3.07 | ||
Enterprise Value to Revenue 3.04 | Enterprise Value to EBITDA 12.21 | Shares Outstanding 2448069888 | Shares Floating 1129611427 |
Shares Outstanding 2448069888 | Shares Floating 1129611427 | ||
Percent Insiders - | Percent Institutions 10.61 |
Analyst Ratings
Rating 4.5 | Target Price 63.06 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sanofi ADR
Company Overview
History and Background
Sanofi ADR (SNY) traces its roots to several predecessor companies, with the modern entity forming in 2004 through the merger of Sanofi-Synthu00e9labo and Aventis. Significant milestones include the development of key vaccines and treatments for cardiovascular disease, diabetes, and rare diseases.
Core Business Areas
- Specialty Care (Sanofi Genzyme): Focuses on rare diseases, multiple sclerosis, oncology, immunology, and other specialty areas.
- Vaccines (Sanofi Pasteur): Develops and manufactures vaccines for various infectious diseases.
- General Medicines: Offers a broad portfolio of established medicines for common ailments.
- Consumer Healthcare: Provides over-the-counter (OTC) products for various health needs.
Leadership and Structure
Sanofi is led by a CEO and has a global organizational structure with operations in numerous countries. The company has multiple divisions focusing on research, development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Dupixent: A biologic medicine for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. Annual revenue is approximately $10 Billion. Competitors include AbbVie's Rinvoq and Pfizer's Cibinqo.
- Vaccines: A broad portfolio of vaccines against influenza, polio, pertussis, and other infectious diseases. Market share varies by vaccine type; Sanofi is a leading global vaccine manufacturer. Competitors include GSK, Merck, and Pfizer.
- Lantus: Long-acting insulin for diabetes treatment. Revenue declined after patent expiration. Competitors include Novo Nordisk and Eli Lilly.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory scrutiny, and patent protection. It is a global market with increasing demand for innovative therapies.
Positioning
Sanofi is a diversified global healthcare company with a strong presence in specialty care, vaccines, and general medicines. Competitive advantages include its R&D capabilities, global reach, and diverse product portfolio.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1 trillion. Sanofi is positioned to capture a significant share through its diversified portfolio and R&D investments.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong presence in key therapeutic areas
- Global reach and distribution network
- Experienced management team
- Robust R&D pipeline
Weaknesses
- Patent expirations on key products
- Exposure to generic competition
- R&D pipeline execution risks
- Dependence on key products
- Regulatory hurdles
Opportunities
- Expansion into emerging markets
- Development of innovative therapies
- Strategic acquisitions and partnerships
- Growth in the vaccine market
- Increasing demand for healthcare solutions
Threats
- Increased competition
- Pricing pressures
- Regulatory changes
- Economic downturns
- Adverse clinical trial results
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- NVS
- ABBV
- LLY
Competitive Landscape
Sanofi competes with other large pharmaceutical companies based on product innovation, pricing, and market access.
Major Acquisitions
Provention Bio
- Year: 2023
- Acquisition Price (USD millions): 2900
- Strategic Rationale: Provention Bio acquisition to secure Tzield (teplizumab), a breakthrough therapy to delay the onset of type 1 diabetes (T1D) in at-risk individuals.
Kadmon Holdings
- Year: 2021
- Acquisition Price (USD millions): 1900
- Strategic Rationale: Kadmon Holdings acquisition broadens Sanofiu2019s transplant medicine portfolio and adds a key product to treat chronic graft-versus-host disease.
Growth Trajectory and Initiatives
Historical Growth: Sanofi's historical growth has been driven by product launches, acquisitions, and market expansion.
Future Projections: Analyst estimates for Sanofi's future growth vary depending on market conditions and product pipeline progress.
Recent Initiatives: Recent initiatives include strategic acquisitions, R&D investments, and expansion into new markets.
Summary
Sanofi ADR presents a diversified pharmaceutical profile with strengths in specialty care and vaccines. Challenges include patent expirations and competitive pressures. Recent strategic acquisitions and focus on innovative therapies position it for future growth, however, R&D success and market access remain crucial for continued success.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Sanofi's Investor Relations Website
- SEC Filings
- Analyst Reports
- Company Press Releases
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a financial professional. Market share information is approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sanofi ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2002-07-01 | CEO & Director Mr. Paul Hudson | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 82878 | Website https://www.sanofi.com |
Full time employees 82878 | Website https://www.sanofi.com | ||
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.